Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $143,025.10 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 3,310 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10. Following the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $13,941.18.
• On Monday, August 5th, Paula Green sold 1,137 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $45,400.41.

Twist Bioscience Trading Up 1.3 %

NASDAQ:TWST opened at $43.34 on Monday. The company has a market capitalization of $2.52 billion, a P/E ratio of -12.90 and a beta of 1.77. The firm has a 50-day moving average price of $44.94 and a two-hundred day moving average price of $43.75. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same period last year, the business earned ($1.01) earnings per share. The company’s revenue for the quarter was up 27.7% on a year-over-year basis. On average, equities research analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Analysts Set New Price Targets

TWST has been the subject of several research analyst reports. The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. TD Cowen upped their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.63.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of TWST. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the second quarter valued at $43,000. Blue Trust Inc. raised its stake in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the 2nd quarter valued at about $61,000. Nisa Investment Advisors LLC boosted its stake in shares of Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after purchasing an additional 546 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after purchasing an additional 524 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.